Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma.

Literature DB >> 962994

Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma.

E S Newlands, C J Oon, J T Roberts, P Elliott, R F Mould, C Topham, F J Madden, K A Newton, G Westbury.

Abstract

Fifty-six patients with disseminated malignant melanoma were randomly allocated to two treatment groups. The first group C received combination chemotherapy consisting of DTIC and ICRF 159. The second group (C+I) received the same chemotherapy but were also immunized with 2 X 10(7) irradiated allogeneic melanoma cells mixed with 50 mug of percutaneous BCG. The survival rates in both treatment groups C and (C+I) were not significantly different, and only minor enhancement of the chemotherapy was found in the (C+I) group. A similar pattern of tissue response was observed in both groups: lymph node, skin and, to some extent liver metastases, respond better than other sites.

Entities: Disease Species

Mesh：

Substances：

Year: 1976 PMID： 962994 PMCID： PMC2025153 DOI： 10.1038/bjc.1976.140

Source DB: PubMed Journal: Br J Cancer ISSN： 0007-0920 Impact factor: 7.640

13 in total

Review 1. Chemotherapy of malignant melanoma.

Authors: J K Luce
Journal: Cancer Date: 1972-12 Impact factor: 6.860

Review 2. Integration of chemotherapy into combined modality therapy of solid tumors. IV. Malignant melanoma.

Authors: R L Comis; S K Carter
Journal: Cancer Treat Rev Date: 1974-12 Impact factor: 12.111

3. Active immunotherapy with B.C.G. for recurrent malignant melanoma.

Authors: J U Gutterman; G Mavligit; C McBride; E Frei; E J Freireich; E M Hersh
Journal: Lancet Date: 1973-06-02 Impact factor: 79.321

4. Chemotherapy of metastatic malignant melanoma. Experience with 73 patients.

Authors: F D Johnson; E M Jacobs
Journal: Cancer Date: 1971-06 Impact factor: 6.860

5. T-lymphocyte responses in patients with malignant melanoma.

Authors: C Butterworth; C J Oon; G Westbury; J R Hobbs
Journal: Eur J Cancer Date: 1974-10 Impact factor: 9.162

6. Prognostic correlations and response to treatment in advanced metastatic malignant melanoma.

Authors: L H Einhorn; M A Burgess; C Vallejos; G P Bodey; J Gutterman; G Mavligit; E M Hersh; J K Luce; E Frei; E J Freireich; J A Gottlieb
Journal: Cancer Res Date: 1974-08 Impact factor: 12.701

7. Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guérin.

Authors: J U Gutterman; G Mavligit; J A Gottlieb; M A Burgess; C E McBride; L Einhorn; E J Freireich; E M Hersh
Journal: N Engl J Med Date: 1974-09-19 Impact factor: 91.245

8. Combination phase 1-II study of imidazole carboxamide (NCS45388).

Authors: D E Wagner; G Ramirez; A J Weiss; G Hill
Journal: Oncology Date: 1972 Impact factor: 2.935

9. Immunization with irradiated tumour cells and specific lymphocyte cytotoxicity in malignant melanoma.

Authors: G A Currie; F Lejeune; G H Fairley
Journal: Br Med J Date: 1971-05-08

10. Autoimmunization with irradiated tumour cells in human malignant melanoma.

Authors: R L Ikonopisov; M G Lewis; I D Hunter-Craig; D C Bodenham; T M Phillips; C I Cooling; J Proctor; G H Fairley; P Alexander
Journal: Br Med J Date: 1970-06-27

9 in total

1. Strategy in the management of melanoma.

Authors: G Westbury
Journal: Proc R Soc Med Date: 1977-06

Review 2. Chemotherapy of malignant melanoma.

Authors: R S Benjamin
Journal: World J Surg Date: 1979-07-30 Impact factor: 3.352

9. Specific active immunotherapy does not prolong survival in surgically treated patients with stage IIB malignant melanoma and may promote early recurrence.

Authors: D W Hedley; T J McElwain; G A Currie
Journal: Br J Cancer Date: 1978-04 Impact factor: 7.640